Taysha Gene Therapies Inc [TSHA] stock is trading at $2.94, down -8.70%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TSHA shares have gain 9.70% over the last week, with a monthly amount glided 30.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Taysha Gene Therapies Inc [NASDAQ: TSHA] stock has seen the most recent analyst activity on April 09, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $9. Previously, Jefferies downgraded its rating to Hold on February 01, 2023, and dropped its price target to $1.50. On January 27, 2023, downgrade downgraded it’s rating to Equal-Weight and revised its price target to $3 on the stock. Goldman downgraded its rating to a Neutral and decreased its price target to $3 on November 09, 2022. Robert W. Baird initiated its recommendation with a Outperform and recommended $26 as its price target on March 09, 2022. Wells Fargo started tracking with a Overweight rating for this stock on March 01, 2022, and assigned it a price target of $25. In a note dated February 18, 2022, SMBC Nikko initiated an Outperform rating and provided a target price of $25 on this stock.
Taysha Gene Therapies Inc [TSHA] stock has fluctuated between $0.50 and $3.89 over the past year. Currently, Wall Street analysts expect the stock to reach $23.38 within the next 12 months. Taysha Gene Therapies Inc [NASDAQ: TSHA] shares were valued at $2.94 at the most recent close of the market. An investor can expect a potential return of 695.24% based on the average TSHA price forecast.
Analyzing the TSHA fundamentals
Taysha Gene Therapies Inc [NASDAQ:TSHA] reported sales of 15.45M for the trailing twelve months, which represents a growth of 44.04%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -4.66%, Pretax Profit Margin comes in at -7.22%, and Net Profit Margin reading is -7.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is 17.38 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.56.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.82 points at the first support level, and at 2.70 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.17, and for the 2nd resistance point, it is at 3.40.
Ratios To Look Out For
For context, Taysha Gene Therapies Inc’s Current Ratio is 4.06. Further, the Quick Ratio stands at 4.06, while the Cash Ratio is 3.93. Considering the valuation of this stock, the price to sales ratio is 35.59, the price to book ratio is 7.33.
Transactions by insiders
Recent insider trading involved Manning Paul B, 10% Owner, that happened on Nov 17 ’23 when 100000.0 shares were purchased. Chief Financial Officer, Alam Kamran completed a deal on Aug 24 ’23 to sell 33000.0 shares. Meanwhile, 10% Owner Manning Paul B bought 16.47 million shares on Aug 16 ’23.
